Jenei, K, Hahn, G, Kesselheim, AS, Tibau, A. Trends in time to withdrawal and full approval of accelerated approval cancer drug indications (1992-2024). Journal Of Cancer Policy. 2025; 45DOI:10.1016/j.jcpo.2025.100597. PMID:40472969. IF:(Q/D).

Remon, J, Bironzo, P, Girard, N, Bigay-Game, L, Juan-Vidal, O, de Castro, J, Reguart, N, Greillier, L, Cousin, S, Dansin, E, Majem, M, Bernabe, R, Martinez, JM, Diaz, M, Meya, A, Alcalá-López, D, Garcia-Sanz, A, Righi, L, Novello, S, Besse, B. Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial. LANCET ONCOLOGY. 2025; 26(9)DOI:10.1016/S1470-2045(25)00300-6. PMID:40907517. IF:35.900(Q1/1D).

Tombal, B, Choudhury, A, Saad, F, Gallardo, E, Soares, A, Loriot, Y, Mcdermott, R, Rodriguez-Vida, A, Velho, PI, Nolè, F, Cruz, F, Roumeguere, T, Daugaard, G, Yamamura, R, Bompas, E, Maroto, P, Veiga, FG, Skoneczna, I, Trindade, KMD, Carcano, FM, Lecouvet, F, Coens, C, Poncet, C, Fournier, B, Gillessen, S, Crua, F. Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial. ANNALS OF ONCOLOGY. 2025; 36(9)DOI:10.1016/j.annonc.2025.05.011. PMID:40450503. IF:65.400(Q1/1D).

de Bono, JS, Williams, A, Melero, I, Jayaram, A, Hawley, JE, de Speville, BD, Moreno, I, Castellano, D, Reig, O, Knapen, DG, Anguera, G, Martinez, J, Gort, E, de Jonge, M, Alonso-Romero, JL, Boni, V, Perez-Gracia, JL, Falcon, A, de Groot, DJ, Pierce, AJ, Leishman, AJ, Lloyd, P, Bartlett, PD, Bland-Ward, P, Chau, A, Song, MJ, Duffy, K, Hashimoto, K, de Vries, E. A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors. CLINICAL CANCER RESEARCH. 2025; 31(16)DOI:10.1158/1078-0432.CCR-24-3581. PMID:40094417. IF:10.200(Q1/1D).

López-Fernández, A, Duran-Lozano, L, Villacampa, G, Pardo, M, Pérez, E, Darder, E, Vallmajó, A, Alfonso, R, Cruellas, M, Roqué, A, Cartró, M, Bareas, A, Carrasco, E, Rezqallah, A, Jimenez-Macedo, AR, Torres-Esquius, S, Torres, M, Lopez, C, Espinosa, M, Teulé, A, Munté, E, Tuset, N, Diez, O, Feliubadaló, L, Lázaro, C, Llort, G, Carver, T, Ficorella, L, Mavaddat, N, Mercadé, A, Antoniou, AC, Brunet, J, Cajal, TRY, Balmaña, J. A randomized study of 2 risk assessment models for individualized breast cancer risk estimation. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2025; 117(8)DOI:10.1093/jnci/djaf067. PMID:40170233. IF:7.200(Q1/2D).

van der Heijden, MS, Powles, T, Gupta, S, Loriot, Y, Galsky, MD, Valderrama, BP, Sridhar, SS, Yu, EY, Iyer, G, Kikuchi, E, Castellano, D, Hoffman-Censits, J, Drakaki, A, Mar, N, Rey, JPM, Vulsteke, C, Arafat, W, Duran, I, Dawson, NA, Swami, U, Gorla, S, Moreno, BH, Yu, X, Lu, YT, Bedke, J. Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma. ESMO Open. 2025; 10(8)DOI:10.1016/j.esmoop.2025.105544. PMID:40795788. IF:8.300(Q1/2D).

Zapatero, A, Alonso-Gordoa, T, Antolín, AR, Couñago, F, Sanmamed, N, Esteban, MD, Valcárcel, ML, Manneh, R, Borque-Fernando, A, González, NS, Maroto, P. Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach. Oncology Reviews. 2025; 19DOI:10.3389/or.2025.1599292. PMID:40787089. IF:(Q/D).

Aggarwal, C, Martinez-Marti, A, Majem, M, Barlesi, F, Carcereny, E, Chu, Q, Monnet, I, Sánchez-Hernández, A, Dakhil, S, Camidge, DR, Pillet, M, Brown, M, Paliompeis, C, Dowson, A, Cooper, ZA, Kumar, R, Herbst, RS. Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer Update From the COAST Randomized Clinical Trial. JAMA Network Open. 2025; 8(7)DOI:10.1001/jamanetworkopen.2025.18440. PMID:40663352. IF:9.700(Q1/1D).